Slide 1A Phase I Study of MK-2206, an Oral Potent Allosteric Akt Inhibitor in Patients with Advanced Solid Tumors Anthony W. Tolcher, 1 Timothy A. Yap, 2 Ivy Fearen, 3 Adekemi…
